Eyenovia Inc HYPD Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.46 down $0.10, 3.91% on Nov 6
Last price · Previous close $2.56
- Market cap
- At the last price
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$2.46down $0.10, 3.91%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.56Nov 5
- Volume317.50KNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume262.01KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.34 to $6.30; now $2.46
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the last price. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
HYPD trailed the S&P 500 in all 6 periods.
| Period | HYPD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | HYPD: down 35.6% S&P 500: down 5.6% | HYPD trailed the S&P 500 by 30.0 percentage points Trailed |
| 3M | HYPD: down 7.9% S&P 500: down 4.1% | HYPD trailed the S&P 500 by 3.8 percentage points Trailed |
| YTD | HYPD: down 30.9% S&P 500: up 8.7% | HYPD trailed the S&P 500 by 39.6 percentage points Trailed |
| 1Y | HYPD: down 56.6% S&P 500: up 10.9% | HYPD trailed the S&P 500 by 67.5 percentage points Trailed |
| Long term | ||
| 3Y | HYPD: down 97.6% S&P 500: up 75.0% −71.3% vs +20.5% a year | HYPD trailed the S&P 500 by 172.6 percentage points Trailed |
| 5Y | HYPD: down 99.2% S&P 500: up 67.8% −62.4% vs +10.9% a year | HYPD trailed the S&P 500 by 167.0 percentage points Trailed |
$10,000 invested in HYPD 5 years ago (Nov 5, 2021) would be worth about $75 as of , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
HYPD trailed the S&P 500 in all 6 periods.
| Period | HYPD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | HYPD: down 35.6% S&P 500: down 5.6% | HYPD trailed the S&P 500 by 30.0 percentage points Trailed |
| 3M | HYPD: down 7.9% S&P 500: down 4.3% | HYPD trailed the S&P 500 by 3.6 percentage points Trailed |
| YTD | HYPD: down 30.9% S&P 500: up 7.8% | HYPD trailed the S&P 500 by 38.7 percentage points Trailed |
| 1Y | HYPD: down 56.6% S&P 500: up 9.7% | HYPD trailed the S&P 500 by 66.3 percentage points Trailed |
| Long term | ||
| 3Y | HYPD: down 97.6% S&P 500: up 68.8% −71.3% vs +19.1% a year | HYPD trailed the S&P 500 by 166.4 percentage points Trailed |
| 5Y | HYPD: down 99.2% S&P 500: up 56.9% −62.4% vs +9.4% a year | HYPD trailed the S&P 500 by 156.1 percentage points Trailed |
$10,000 invested in HYPD 5 years ago (Nov 5, 2021) would be worth about $75 as of , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$796.00
Closing high on . Now 99.7% below that record.
Split-adjusted daily closes since Jan 25, 2018.
Stock splits
1
1-for-80 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $1.40Mup 3,052.0%
- Net income
- $27.33M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $1.63K | −$7.89M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $28.09K | −$19.95M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $14.72K | −$3.48M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$8.69M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $302.51K | $6.63M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $496.23K | −$39.77M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $244.27K | $13.63M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $357.69K | $46.84M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $14.00M | −$12.78M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$28.01M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $3.79K | −$27.26M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $57.34K | −$49.82M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $813.46K | −$45.31M | Paused See the note under the price. |
Margins
- Gross 78.4%
- Operating 303.5%
- Net 1,951.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$13.95MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$13.97MLast 12 months
- Capital spending$22.96KLast 12 months
- −996.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $50.91MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $109.48MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$8.91MAs of Jun 30, 2026
- Net cash$100.57MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 2.34As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.09As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 6 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 40.2%Last 12 months
Over the last 12 months, Eyenovia’s net income was 40.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 34.4%Last 12 months
Over the last 12 months, Eyenovia’s net income was 34.4% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Eyenovia Inc
Eyenovia, Inc. is an ophthalmic technology company developing its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is targeted at both home use for ocular lubrication as well as chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for improved treatment compliance.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Texas, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
HYPD news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
HYPD stock FAQ
What is HYPD stock’s price today?
Eyenovia (HYPD) traded at $2.46 as of , down $0.10 (3.91%) from the previous close of $2.56. Over the past 52 weeks it has traded between $2.34 and $6.30.
If you invested $1,000 in HYPD 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in HYPD on would be worth about $8 as of , a total return of −99.2%. The same $1,000 would be worth $434 if invested one year ago. Past performance doesn’t predict future returns.
How much revenue does Eyenovia make?
Eyenovia reported $1.4 million of revenue over the four quarters to , up 3,052.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $357.7 thousand.
Is Eyenovia profitable?
Yes. Eyenovia earned $27.3 million of net income over the four quarters to , a net margin of 1,951.4%, and its operating margin was 303.5% (what margins tell you).
Does HYPD pay a dividend?
Eyenovia hasn’t paid a dividend in the last twelve months.
What is HYPD’s 52-week high and low?
Over the past 52 weeks HYPD has traded as low as $2.34 and as high as $6.30. At $2.46 as of , it is 61.0% below that high and 5.1% above the low.
What is HYPD’s all-time high?
HYPD’s highest closing price was $796.00 on , adjusted for stock splits. At $2.46 as of , it is 99.7% below that record.
Has HYPD stock ever split?
Yes, once: 1-for-80 on .
How has HYPD stock performed?
Including dividends and measured to the last price on , HYPD has returned −30.9% so far this year and −56.6% over the past year, and −99.2% over five years (−62.4% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Eyenovia in?
Eyenovia is in the Healthcare sector and the Biotechnology industry, and is headquartered in Texas, USA.
What exchange does HYPD trade on?
Eyenovia trades on the Nasdaq under the ticker symbol HYPD. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.